Literature DB >> 1153442

Delta9-tetrahydrocannabinol and pentobarbital as discriminative cues in the Mongolian Gerbil (Meriones unguiculatus)

T U Järbe, J O Johansson, B G Henriksson.   

Abstract

Male Mongolian gerbils were trained to escape electric shocks in a T-shaped maze contingent upon the presence or absence of certain drug effects (state-dependency; StD). The drug discriminative cues used were those of either delta9-tetrahydrocannabinol (THC) or pentobarbital (P-barb.) vis-à-vis the respective vehicles. Several doses of THC (0.5-16.0 mg/kg) were used and compared with P-barb. (20.0 mg/kg), a dose at which the most rapid drug discrimination occurs in the rat. When drug discrimination was established dose-time- and transfer characteristics for the training drugs were studied. Possible potentiation and antagonism was also examined in the pentobarbital trained gerbils. It was found that none of the THC doses were discriminated as rapidly as that of P-barb. Decreasing the amounts of training drug administered or increasing the injection-test intervals resulted in a decline of the number of drug associated choices. There was a maximum of 40% drug choices between THC and P-barb at the transfer tests. Mixtures of the two compounds increased the number of drug choices in an additive or even more than additive manner. Amphetamine (4.0 mg/kg) did not interact with the P-barb. induced choice responding. The analeptic drug, bemegride was found effective in antagonizing the P-barb. cued choice behavior.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1153442     DOI: 10.1016/0091-3057(75)90048-9

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  14 in total

1.  Discriminative effects of combinations of delta 9-tetrahydrocannabinol and pentobarbital in pigeons.

Authors:  T U Järbe; G C Ohlin
Journal:  Psychopharmacology (Berl)       Date:  1979-06-21       Impact factor: 4.530

2.  Effects of chlormethiazole (Heminevrin) on drug discrimination and open-field behavior in gerbils.

Authors:  M D Swedberg; P Loman; T U Järbe
Journal:  Psychopharmacology (Berl)       Date:  1978-10-31       Impact factor: 4.530

3.  Characteristics of pentobarbital discrimination in the gerbil: transfer and antagonism.

Authors:  T U Järbe
Journal:  Psychopharmacology (Berl)       Date:  1976-08-26       Impact factor: 4.530

4.  Discriminative stimulus properties of d-amphetamine-pentobarbital combinations.

Authors:  J M Witkin; R B Carter; L A Dykstra
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

5.  Discriminative properties of pentobarbital after repeated noncontingent exposure in gerbils.

Authors:  T U Järbe; B Holmgren
Journal:  Psychopharmacology (Berl)       Date:  1977-06-06       Impact factor: 4.530

6.  Morphine as a discriminative cue in gerbils: drug generalization and antagonism.

Authors:  T U Järbe; C Rollenhagen
Journal:  Psychopharmacology (Berl)       Date:  1978-07-19       Impact factor: 4.530

7.  Iron Homeostasis and Metabolism: Two Sides of a Coin.

Authors:  Vivek Venkataramani
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

8.  Evaluation of cannabinoid agonists using punished responding and midazolam discrimination procedures in squirrel monkeys.

Authors:  Marcus S Delatte; Carol A Paronis
Journal:  Psychopharmacology (Berl)       Date:  2007-09-19       Impact factor: 4.530

9.  Discriminative stimulus properties of delta9-tetrahydrocannabinol (THC) in C57Bl/6J mice.

Authors:  Robert E Vann; Jonathan A Warner; Kristen Bushell; John W Huffman; Billy R Martin; Jenny L Wiley
Journal:  Eur J Pharmacol       Date:  2009-05-23       Impact factor: 4.432

10.  Substitution profile of Delta9-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in humans discriminating Delta9-tetrahydrocannabinol.

Authors:  Joshua A Lile; Thomas H Kelly; David J Pinsky; Lon R Hays
Journal:  Psychopharmacology (Berl)       Date:  2008-11-19       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.